Antiangiogenesis Therapy for Endometriosis

Annemiek Nap, Annemiek W Nap, Arjan W Griffioen, Gerard A J Dunselman, Jessica C.A. Bouma-ter Steege, Victor L. Thijssen, Victor L J L Thijssen, J.L.H. Evers, Johannes L H Evers, Patrick G Groothuis
The Journal of clinical endocrinology and metabolism · 2004 · vol. 89(3) , pp. 1089–1095 · doi:10.1210/jc.2003-031406 · PMID:15001592 · W2086233980
article OA: closed CC0 ⤵ 190 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Angiostatic compounds significantly reduced microvessel density and the growth of established endometriosis lesions in a mouse model by inhibiting angiogenesis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

It is known that angiogenesis is of pivotal importance for the development of endometriosis. However, in the treatment of endometriosis patients, prevention of endometriosis lesion development only will not be sufficient as a therapy. Treatment options, aimed at interfering with established lesions, have to be developed. In this study we evaluated whether inhibition of angiogenesis by angiostatic therapy is also effective in antagonizing the sustentation of endometriosis. We evaluated the effect of the angiostatic compounds antihuman vascular endothelial growth factor, TNP-470, endostatin, and anginex on the growth of established endometriosis lesions in the nude mouse model. We show that human endometrium in the proliferative endometrium is highly angiogenic and that vascular endothelial growth factor-A is the most important angiogenesis promotory factor. The angiostatic compounds significantly decreased microvessel densities and the number of established endometriosis lesions. In the remaining lesions, the number of pericyte-protected vessels is not different in control and treated mice; however, the number of unprotected vessels was significantly reduced in the groups treated with the angiostatic agents. Our data demonstrate that inhibitors of angiogenesis effectively interfere with the maintenance and growth of endometriosis by inhibiting angiogenesis. This suggests that the use of angiostatic agents may be promising as a therapy for endometriosis.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Angiogenesis Inhibitors Endometriosis Neovascularization, Pathologic Sesquiterpenes Adult Angiogenesis Inhibitors Animals Cyclohexanes Endometriosis Endometriosis Endometrium Endometrium Endometrium Endostatins Endostatins Female Humans Mice Mice, Nude Neovascularization, Pathologic

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (30)

Cited by (50)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:12:38.158000+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK